MARINE PRODUCTS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MARINE PRODUCTS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $267.32M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $241.33M | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $207.06M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $171.05M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $168.29M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $148.95M | Feb 27, 2015 |
| FY2013 | Dec 31, 2011 | $106.44M | Mar 6, 2014 |
| FY2012 | Dec 31, 2010 | $101.01M | Mar 1, 2013 |
| FY2011 | Dec 31, 2009 | $39.44M | Feb 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.78M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $45.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $90.38M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $93.72M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $68.27M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $53.61M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $65.39M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $66.32M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $59.02M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $50.47M | Feb 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.38M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $17.85M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $41.70M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $40.35M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $29.03M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $19.44M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $28.24M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $28.49M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $19.30M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $16.75M | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $18.27M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $49.20M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $51.80M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $36.39M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $24.36M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $34.14M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $35.39M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $29.76M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $23.05M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $822.0K | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $960.0K | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $858.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $663.0K | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $743.0K | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $1.07M | Feb 29, 2016 |
| FY2014 | Dec 31, 2012 | $768.0K | Feb 27, 2015 |
| FY2013 | Dec 31, 2011 | $789.0K | Mar 6, 2014 |
| FY2012 | Dec 31, 2010 | $489.0K | Mar 1, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.75M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $27.38M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $43.21M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $41.92M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $31.88M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $29.24M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $31.26M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $30.94M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $29.26M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $27.42M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.46M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $29.53M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $56.85M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $49.35M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $457.0K | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $29.87M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $33.92M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $22.78M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $29.64M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $15.84M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.17M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.25M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $2.10M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $2.33M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.15M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.41M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $1.94M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $171.25M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $193.80M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $163.72M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $132.84M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $119.42M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $104.76M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $100.88M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $95.90M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $88.53M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.27M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $42.24M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $42.21M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $39.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $34.32M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $34.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $27.55M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $25.67M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $26.30M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $23.08M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.97M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $129.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $151.59M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $124.38M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $98.53M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $84.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $77.21M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $75.21M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $69.60M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $65.45M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.31M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.31M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.31M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.31M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $3.31M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.31M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.31M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $3.31M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.31M | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $125.53M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $148.14M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $122.95M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $97.70M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $83.08M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $76.57M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $73.95M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $68.13M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $64.14M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $31.57M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $19.80M | Feb 26, 2021 |
| FY2020 | Dec 31, 2018 | $8.75M | Feb 26, 2021 |
| FY2020 | Dec 31, 2017 | $7.68M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $2.62M | Feb 28, 2020 |
| FY2018 | Dec 31, 2015 | $7.99M | Feb 28, 2019 |
| FY2017 | Dec 31, 2014 | $4.07M | Feb 28, 2018 |
| FY2016 | Dec 31, 2013 | $5.11M | Feb 28, 2017 |
| FY2015 | Dec 31, 2012 | $1.65M | Feb 29, 2016 |
| FY2014 | Dec 31, 2011 | $956.0K | Feb 27, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 28, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 34.71M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 34.47M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 34.22M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 33.99M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 33.87M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 33.87M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 34.33M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 34.57M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 34.86M | Feb 28, 2018 |